While DNA is the information archive and “hardware” of the cell, it is the proteins that do all of the work- the “software” of the cell. Moreover, it is through key protein post-translational modifications such as phosphorylation, acetylation, methylation, etc that functionally control nearly all biochemical processes and these proteins and phosphoproteins, etc. are the direct targets of nearly all FDA approved and Phase II/III precision therapeutics in oncology today. 

We have successfully developed, validated and deployed the first functional platform using a combined laser capture micro dissected (LCM) - reverse phase protein array (RPPA) approach within a CLIA/CAP accredited laboratory environment for clinical applications today in the precision oncology space.

This webinar will focus on clinical applications of the LCM-RPPA assay platform in precision oncology in both the early stage (neoadjuvant) and late-stage/metastatic setting for optimized patient selection and predictive biomarker applications.